Britain’s medical device watchdog has published 44 recommendations calling for updates to its policies to govern artificial intelligence in the NHS. The Medicines and Healthcare Products Regulatory Agency warns that existing frameworks cannot manage software that continuously learns, adapts, and drifts after initial approval.
The current medical-devices regulatory framework in the UK was built for a different era of medicine, designed primarily around physical hardware like hip replacements, knee replacements, stethoscopes, and plasters. According to the Medicines and Healthcare Products Regulatory Agency, those established rules fail to address the unique nature of modern software tools deployed in clinical settings.
Lawrence Tallon and MHRA Warnings on Adaptive AI Software
While simple software trained to spot known symptoms on static scans can function under current guidelines, more advanced models behave entirely differently. MHRA chief Lawrence Tallon explained that regulatory challenges multiply once technology enters clinical environments.
“Unlike most of the medical products we’re used to regulating, these products continue to change after the point of authorization. As new data gets fed in, they learn, they adapt, they drift.”
Lawrence Tallon, MHRA chief
Tallon noted that artificial intelligence will soon become an ordinary part of British healthcare delivery. He emphasized that patients must see these tools integrated in a way that they can maintain their trust and their confidence in what’s happening
across the health service.
Independent Commission Report and Patient Consultation Data
The push for legislative overhaul stems from a comprehensive report compiled by an independent commission. That inquiry gathered input from more than 12,000 individuals, incorporating perspectives directly from patients and clinical professionals.
Among the 44 distinct recommendations published by the watchdog are proposals to continuously monitor deployed products. Under the suggested framework, regulators would hold the authority to strip approval if an algorithm malfunctions or loses efficacy over time. The proposals also demand that patients receive explicit notification whenever artificial intelligence contributes to their care, alongside accessible pathways to inspect product details.
Proposed Supervised Trials and Regulatory Penalties
To safely accelerate software adoption, the watchdog proposed an L plate
system designed to facilitate closely supervised clinical trials of emerging models by healthcare professionals. Concurrently, the framework introduces enforcement mechanisms giving authorities the power to penalize developers whose products fall short of mandatory safety standards.
Despite these proactive steps domestically, regulatory authorities acknowledge that international alignment remains elusive.
“I don’t think at this moment in time we can point to a single country, a single regulatory framework, and say that they have absolutely cracked it.”
Lawrence Tallon, MHRA chief
Widespread GP Integration and Patient Privacy Concerns
The regulatory push arrives as automated tools embed themselves deeper into everyday practice. Large language model scribe systems are already utilized by 40 percent of UK-based general practitioners to record patient consultations and generate clinical notes.
However, increased reliance introduces distinct friction points regarding patient disclosure and privacy. A University of Edinburgh study revealed that patients express a reduced willingness to share sensitive disclosures—including history related to substance abuse—if they know an artificial intelligence processor handles the conversation. Professor Henrietta Hughes noted that while some patients opt out of AI-assisted recording entirely, attending physicians retain sole professional responsibility for identifying and correcting any errors generated within the automated consultation notes.
Worth a look